Dynavax Tech (DVAX) Said TOLAMBA Fails To Achieve Primary Endpoint, Discontinues Development
Tweet Send to a Friend
Dynavax Technologies Corporation (Nasdaq: DVAX) reported primary endpoint data from a chamber study of TOLAMBA that showed a measurable clinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
